论文部分内容阅读
目的研究促甲状腺激素受体(TSHR)、碘钠泵(NIS)在甲状腺癌中的表达,探讨其在人甲状腺癌治疗中的作用。方法采用免疫组织化学SABC法,检测TSHR、NIS在45例人正常甲状腺组织、45例乳头状甲状腺癌及21例未分化甲状腺癌中的表达。结果TSHR及NIS在人正常甲状腺组织的表达均高于其在乳头状甲状腺癌和未分化甲状腺癌中的表达。在人正常甲状腺组织,TSHR和NIS蛋白均定位于滤泡上皮细胞膜上;在乳头状甲状腺癌组织,TSHR蛋白定位于细胞膜和细胞质中,NIS蛋白仅在细胞质中有阳性表达;在未分化甲状腺癌,TSHR和NIS均定位于细胞质。结论TSHR、NIS的定位及表达水平与甲状腺癌的分化程度密切相关,可能成为预测甲状腺癌促甲状腺激素抑制治疗及131I治疗是否有效的指标。
Objective To study the expression of thyroid stimulating hormone receptor (TSHR) and sodium iodide pump (NIS) in thyroid carcinoma and to explore its role in the treatment of human thyroid cancer. Methods Immunohistochemical SABC method was used to detect the expression of TSHR and NIS in 45 cases of normal thyroid tissue, 45 cases of papillary thyroid carcinoma and 21 cases of undifferentiated thyroid carcinoma. Results The expression of TSHR and NIS in human normal thyroid tissue were higher than those in papillary thyroid carcinoma and undifferentiated thyroid carcinoma. In normal human thyroid tissue, both TSHR and NIS proteins are located on the follicular epithelial cell membrane. In papillary thyroid carcinoma, TSHR protein is located in the cell membrane and cytoplasm, and NIS protein is only expressed in cytoplasm. In undifferentiated thyroid carcinoma , TSHR and NIS are localized in the cytoplasm. Conclusion The localization and expression level of TSHR and NIS are closely related to the degree of differentiation of thyroid carcinoma and may be an index for predicting the thyroid-stimulating suppression and 131I treatment in thyroid cancer.